Fer­ti­PRO­TEKT

• A Sys­tem­at­ic Review of the Gon­ado­tox­icity of Osteo­sar­coma and Ewing’s Sarcoma Chemo­ther­apies in Post­pu­ber­tal Females and Males April 17, 2024
  Data on gon­ado­tox­icity of chemo­ther­apies are essential to better counsel young females and males about the risk of infer­til­ity and to better indicate fertility pre­ser­va­tion measures before cancer therapies. However, such data have not recently been reviewed for bone cancer. Therefore, a sys­tem­at­ic lit­er­at­ure search was conducted con­sid­er­ing papers published since 2000. This study is […]
  Susanna Weidlinger
• Eval­u­ation of the Gon­ado­tox­icity of Cancer Therapies to Improve Coun­sel­ing of Patients About Fertility and Fertility Pre­ser­va­tion Measures: Protocol for a Ret­ro­spect­ive Sys­tem­at­ic Data Analysis and a Pro­spect­ive Cohort Study March 20, 2024
  CONCLUSIONS: The study can be expected to bridge the data gap regarding the gon­ado­tox­icity of cancer therapies to better counsel patients about their infer­til­ity risk and their need to undergo fertility pre­ser­va­tion pro­ced­ures. Initial data are expected to be uploaded on the FertiTOX platform in 2026.
  Michael von Wolff
• Indic­a­tion and imple­ment­a­tion of fertility pre­ser­va­tion measures in female cancer patients June 14, 2023
  The aspects of fertility pre­ser­va­tion in women prior to surgical, gon­ado­tox­ic or radiation therapy represent a chal­len­ging topic in many dis­cip­lines and often in an inter­dis­cip­lin­ary setting. Within an often short period of time, indi­vidu­al coun­selling and con­sid­er­a­tion must be given as to whether fertility-pro­tect­ive measures are useful. The imple­ment­a­tion is ulti­mately decided by the […]
  Ariane Germeyer
• National oncofer­til­ity regis­tries around the globe: a pilot survey May 24, 2023
  CONCLUSION: Although oncofer­til­ity services are expanding globally, very few countries have well-estab­lished official national oncofer­til­ity regis­tries. By reviewing such a global landscape, we highlight the urgent need for having a well-estab­lished official national oncofer­til­ity registry in each country to monitor oncofer­til­ity services in a way that best serves patients.
  Noelle Ozimek
• Determ­in­ants of trans­plant­a­tion success with cryo­p­reserved ovarian tissue: data from 196 women of the Fer­ti­PRO­TEKT network October 22, 2022
  STUDY QUESTION: What are the pregnancy and live birth rates for ovarian tissue trans­plant­a­tion and which factors are asso­ci­ated with the success rate?
  L Lotz
• Trans­plant­a­tion of cryo­p­reserved ovarian tissue in a series of 285 women: a review of five leading European centers May 2, 2021
  The feas­ib­il­ity of freezing and thawing ovarian tissue is nowadays widely doc­u­mented. However, ovarian tissue trans­plant­a­tion (OTT) is happening at a much slower pace, and clinical exper­i­ence is somewhat limited. In this review, five European centers present their col­lect­ive exper­i­ence of trans­plant­ing ovarian tissue in 285 women. The focus is on surgical tech­niques and OTT […]
  Marie-Madeleine Dolmans
• Cryo­p­reser­va­tion and Thawing of Human Ovarian Cortex Tissue Slices August 16, 2020
  Cryo­p­reserved ovarian cortex tissue can be used to improve or restore female fertility. It can be used for cancer patients to restore fertility after chemo­ther­apy treatment or for social reasons for women who want to postpone their pregnancy wish. In order to preserve ovarian tissue viability in these cases, the tissue needs to be stored […]
  Jana Lieben­thron
• Moth­er­hood after cancer: fertility and util­isa­tion of fertility-pre­ser­va­tion methods May 8, 2020
  CONCLUSION: After cancer and gon­ado­tox­ic treatment, women’s desire to have a child is sub­stan­tial. In this study, the rate of spon­tan­eous preg­nan­cies and births was 20% 6 years after gon­ado­tox­ic therapies. Not every woman, however, has the oppor­tun­ity to conceive: factors impairing fertility include ongoing cancer treatment or per­sist­ent disease, no partner, no menstrual cycle, […]
  Maren Goeck­en­jan
• Serum anti-Mullerian hormone (AMH) con­cen­tra­tion has limited pro­gnost­ic value for density of prim­or­di­al and primary follicles, ques­tion­ing it as an accurate parameter for the ovarian reserve March 8, 2020
  CONCLUSIONS: Serum AMH levels have limited pro­gnost­ic value for the follicle density and therefore for the real ovarian reserve.
  Michael von Wolff
• Ovarian Tissue Trans­plant­a­tion: Exper­i­ence From Germany and Worldwide Efficacy August 22, 2019
  Extrac­tion of ovarian tissue prior to oncologic therapy and sub­sequent trans­plant­a­tion is being performed increas­ingly often to preserve fertility in women. The procedure can be performed at any time of the cycle and, therefore, generally does not lead to any delay in onco­lo­gic­al therapy. Success rates with trans­plant­a­tion of cryo­p­reserved ovarian tissue have reached promising […]
  Laura Lotz
• The effect of bpV(HOpic) on in vitro activ­a­tion of prim­or­di­al follicles in cultured swine ovarian cortical strips May 16, 2019
  The vanadate-deriv­at­ive dipo­tassi­um bisperoxo (5‑hydroxy-pyridine-2-carboxyl­ic) oxovanadate (V) (bpV(HOpic)), a phar­ma­co­lo­gic­al inhibitor of phos­phata­se and tensin homolog (PTEN), has been used in ovarian follicle culture systems for activ­a­tion of fol­licu­lar growth in vitro and suggested to be respons­ible for prim­or­di­al follicle survival through indirect Akt activ­a­tion. For pig ovarian tissue, it is still not clear which […]
  Nathalie Raffel
• Fer­ti­PRO­TEKT, Oncofer­til­ity Con­sor­ti­um and the Danish Fertility-Pre­ser­va­tion Networks — What Can We Learn From Their Exper­i­ences? May 10, 2019
  Fertility pre­ser­va­tion is an increas­ingly important dis­cip­line. It requires close coordin­a­tion between repro­duct­ive medicine spe­cial­ists, repro­duct­ive bio­lo­gists, and onco­lo­gists in various dis­cip­lines. In addition, it rep­res­ents a par­tic­u­lar health policy challenge, since fertility-pro­tec­tion measures are to be under­stood as a treatment for side effects of gon­ado­tox­ic treat­ments and would therefore normally have to be reimbursed […]
  Michael von Wolff
• Overnight ovarian tissue trans­port­a­tion for cent­ral­ized cryo­bank­ing: a feasible option February 9, 2019
  CONCLUSIONS: Overnight trans­port­a­tion for central cryo­bank­ing is a feasible concept that results in high repro­du­cible success rates through stand­ard­ized pro­fes­sion­al tissue freezing and storage.
  Jana Lieben­thron
• Fertility pre­ser­va­tion: ovarian response to freeze oocytes is not affected by different malignant diseases-an analysis of 992 stim­u­la­tions June 6, 2018
  CONCLUSIONS: As ovarian response is not affected by the type of cancer, ovarian stim­u­la­tion can be performed with the same oocyte yield in different malignant diseases. However, oocyte yield is reduced if ovarian surgery is required and in older women.
  M von Wolff
• Clinical Practice Guidelines for Fertility Pre­ser­va­tion in Pediatric, Adoles­cent, and Young Adults with Cancer March 28, 2018
  In recent years, more cancer patients are achieving long-term survival owing to advances in treatment. However, cancer treatment can cause gonadal dys­func­tion that leads to loss of fertility. Thus, it is important for clinical onco­lo­gists to consider fertility pre­ser­va­tion in children, adoles­cents, and young adults with cancer who are expected to have a favorable outcome […]
  Nao Suzuki
• Fertility Pre­ser­va­tion in Pre­pu­ber­tal und Pubertal Children and Adoles­cents February 9, 2018
  CONCLUSION: In children and adoles­cents, measures of fertility pre­ser­va­tion should be con­sidered in cases of highly gon­ado­tox­ic therapies, and appro­pri­ate advice should be given by specialists.
  Nicole Sänger
• Fertility pro­tec­tion: com­plic­a­tions of surgery and results of removal and trans­plant­a­tion of ovarian tissue December 5, 2017
  Fertility-pre­serving measures are becoming important for patients receiving onco­lo­gic­al treatment. One method involves cryo­p­reser­va­tion of ovarian tissue and trans­plant­ing it when treatment is completed. We report com­plic­a­tions resulting from surgical and fertility medicine, and the results of pro­ced­ures for the removal and trans­plant­a­tion of ovarian tissue carried out within the Fer­ti­Pro­tekt network. A survey using […]
  Matthias W Beckmann
• Practical recom­mend­a­tions for fertility pre­ser­va­tion in women by the Fer­ti­PRO­TEKT network. Part II: fertility pre­ser­va­tion tech­niques November 29, 2017
  CONCLUSIONS: Fertility pre­ser­va­tion in women provides realistic chances of becoming pregnant. The choice of technique needs to be based on the time required, the woman’s age, its risks and efficacy, and the indi­vidu­al pref­er­ence of the patient.
  Michael von Wolff
• Practical recom­mend­a­tions for fertility pre­ser­va­tion in women by the Fer­ti­PRO­TEKT network. Part I: Indic­a­tions for fertility pre­ser­va­tion November 28, 2017
  CONCLUSION: The decision for or against fertility pre­ser­va­tion depends on the prognosis, the risks to fertility and indi­vidu­al factors such as pro­spect­ive family planning.
  A N Schüring
• Chapter 15 Devel­op­ment of a Nation­wide Network for Ovarian Tissue Cryo­p­reser­va­tion April 20, 2017
  Ovarian tissue cryo­p­reser­va­tion is gaining much interest since the pub­lic­a­tion of the first live birth after retrans­plant­a­tion of frozen-thawed tissue in 2004 (Donnez et al., Lancet 364:1405–1410, 2004). In contrast to cryo­p­reser­va­tion of gametes and embryos, ovarian tissue freezing is a complex requiring a proper approach in order to make this a viable option for […]
  Jana Lieben­thron